

Katrina G Millard

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8257074/katrina-g-millard-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21
papers

4,164
citations

17
h-index

27
g-index

27
ext. papers

6,340
ext. citations

34.1
avg, IF

5.38
L-index

#	Paper	IF	Citations
21	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.. <i>Lancet Microbe, The</i> , 2022 , 3, e203-e214	22.2	2
20	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. 2022 ,		3
19	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. <i>Nature</i> , 2022 ,	50.4	14
18	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021 ,	50.4	69
17	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies 2021 ,		24
16	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year 2021 ,		19
15	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021 , 595, 426-431	50.4	247
14	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021 , 591, 639-644	50.4	652
13	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021 , 592, 616-622	50.4	730
12	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021 , 54, 1853-1868.e7	32.3	83
11	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants 2021 ,		54
10	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020 , 182, 828-842.e16	56.2	485
9	Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals 2020 ,		60
8	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies 2020 ,		30
7	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020 , 584, 437-442	50.4	1167
6	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. <i>PLoS ONE</i> , 2019 , 14, e0219142	3.7	33
5	Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. <i>Journal of Experimental Medicine</i> , 2018 , 215, 2311-2324	16.6	55

4	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 2018 , 92,	6.6	32
3	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. <i>Nature</i> , 2018 , 561, 479-484	50.4	250
2	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. <i>Nature Medicine</i> , 2018 , 24, 1701-1707	50.5	142
1	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7